CFDE Data Portal | Search TMCC1-DT

	Label	Description
	TMCC1-DT Gene (Entity type)	ENSG00000271270 - TMCC1 divergent transcript
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125014 enzalutamide prostate gland 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE166315 1 V 0 DOCETAXEL MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 6 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS

TMCC1-DT

ENSG00000271270 - TMCC1 divergent transcript

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 3 human up

A Gene Set from LINCS

GSE125014 enzalutamide prostate gland 1 v 5 human up

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 11 human dn

A Gene Set from LINCS

GSE166315 1 V 0 DOCETAXEL MOUSE UP

A Gene Set from LINCS

GSE146358 dopamine 5 v 2 human up

A Gene Set from LINCS

GSE108464 AZ-628 6 v 15 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.